C Ray Therapeutics is a Chengdu-based radiopharmaceutical contract research, development, and manufacturing organization (CRDMO) that this week highlighted its expanding capabilities ahead of its presence at ANZSNM2026 in Canberra from May 15–17. The company will showcase its services at Booth 48 and is actively seeking discussions on development partnerships, isotope pilot projects, and clinical research collaborations.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
C Ray Therapeutics emphasized its integrated service offering spanning precursor compound selection, pre-clinical evaluation, CMC development, IND filing, clinical supply, and commercial cGMP manufacturing. The company reports having completed more than 100 CRDMO projects across preclinical, IND-enabling, investigator-initiated, and clinical stages, including two programs that have advanced to Phase III development.
The firm also highlighted its expertise in high-value radiotherapy isotopes, noting that 23 of its projects involve actinium-225 labeling, alongside broader work with lutetium-177 radioligands. This focus positions C Ray Therapeutics within a growing niche of targeted radioligand therapies that are attracting increasing attention from oncology and nuclear medicine developers.
Its planned participation in ANZSNM2026 underscores a strategic push to deepen relationships within the Australia and New Zealand nuclear medicine ecosystem and broaden its international client base. For the company’s future prospects, successful conversion of conference engagement into new development or manufacturing mandates could enhance revenue visibility and strengthen its role in the global radiopharmaceutical supply chain, marking a constructive week of profile-building and business development activity.